Evidence map›Paper›PMID 41068115›Full record

ReviewNature communications2025

Incorporating meningeal immunity into vaccine development.

Manisha Menon, Colin N Haile, David J Dowling

Abstract readReview
In one paragraph

Review in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Manisha MenonPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7152-3752
Colin N HaileDepartment of Psychology/TIMES, University of Houston, Houston, TX, USA.
David J DowlingPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA. david.dowling@childrens.harvard.edu.ORCID http://orcid.org/0000-0003-1095-6156

Funding

Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly75N93019C00044 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2019 to 2023
$11.0M
NIAID NIH HHS 75N93019C00044NIAID NIH HHS 75N93020C00038
6 · The paper itself

Abstract

Meningeal immunity, a less-studied aspect of neuroimmune interactions, has recently come under the spotlight owing to the characterization of meningeal lymphatic vessels draining of the central nervous system (CNS). This changing landscape has begun to impact how vaccinologists and immunologists approach early pre-clinical vaccine development, including decentering the antigen, with a greater focus on the role of formulation science and route of delivery. Here, we review the current state of how concepts emerging from meningeal immunity are being incorporated into modern vaccine innovation, discovery, and development.

Indexed as

MeningesVaccine DevelopmentVaccinesAnimalsHumansVaccines

Identifiers

PMID41068115
PMCPMC12511393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.